10x Genomics Consensus Price Target Increased by 13.66% to $60.62
The average one-year price target for 10x Genomics (NASDAQGS:TXG) (LSE:0A88) has been revised to $60.62 / share. This is an increase of 13.66% from the prior estimate of $53.33 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute an investment recommendation.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $40.40 to a high of $94.50 / share. The average price target represents a decrease of 31.71% from the latest reported closing price of $88.76 / share.
The median target rose to $57.12 from $51.00, representing an absolute median change of $6.12. The current mean-median gap is $3.50. The target range widened, with the current target range width at $54.10 compared to the prior width of $33.10, which is a change of +63.44%.
Looking at the target history, the mean target has increased consecutively 9 times. The mean target was $40.96 on August 5, 2026, rising to $48.18 on August 28, 2026, then to $53.33 on September 15, 2026, and reaching $60.62 on October 2, 2026. This represents a target change of +115.20% since the 90-day baseline date of June 30, 2026. The observed twelve-month high mean target is $60.62 as of October 2, 2026, and the observed twelve-month low mean target is $15.08 as of November 9, 2025.
As context for these revisions, the company's stock price closed at $88.76 on October 1, 2026. This represents a one-week price change of +5.53% from the baseline close of $84.11 on September 24, 2026, and a one-month price change of +47.98% from the baseline close of $59.98 on September 1, 2026. In its latest earnings report on August 6, 2026, 10x Genomics reported an actual EPS of -0.14, compared to the estimated EPS of -0.246. Actual revenue was $151,036,000.00, representing a +1.88% surprise over the estimated revenue of $148,255,516.00.
10x Genomics, Inc., based in the United States, operates within the biotechnology industry, specializing in developing and manufacturing advanced genetic sequencing platforms. Its key projects include the Chromium and Visium platforms. Under the GICS classification, the company is categorized in the Financials sector, Capital Markets industry, and Asset Management & Custody Banks sub-industry. Within this sub-industry, 32 companies are covered, with 7 raised, 9 lowered, and 16 unchanged. The sub-industry median revision percent is 0.00%, and the median implied change percent is +26.88%.
Recent analyst actions include Argus Research initiating coverage on September 28, 2026, with a Buy rating. Piper Sandler maintained a Neutral rating on September 28, 2026, Leerink Partners maintained a Market Perform rating on September 29, 2026, and UBS maintained a Neutral rating on September 9, 2026. The recommendation trend as of September 1, 2026, shows 5 strong buy, 4 buy, and 11 hold recommendations, which is unchanged from the August 1, 2026, period.
Among its peers, only Illumina saw a positive target revision, while Pacific Biosciences of California and Standard BioTools remained unchanged.
| Company | Target revision | Implied change |
|---|---|---|
| Illumina | +3.77% | -22.74% |
| Pacific Biosciences of California | 0.00% | -12.34% |
| Standard BioTools | 0.00% | +117.08% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.